Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| Uliledlimab (TJD5) (TJ004309) +/- toripalimab & +/- pembrolizumab | Cancer, Non-small cell lung carcinoma | Phase 2 | Dec 31, 2026 | — |
| Givastomig (TJ-CD4B/ABL111) combo w/ nivolumab + chemo | 1L Gastric Cancers | Phase 1b | Oct 25, 2026 | — |
Upcoming milestones
Company profile
I-Mab is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
1L Gastric Cancers
Cancer, Non-small cell lung carcinoma
Data readout